Amneal Pharmaceuticals (AMRX) Capital Leases (2017 - 2026)

Amneal Pharmaceuticals has reported Capital Leases for 10 years, with the latest figure at $54.6 million in Q2 2026.

• On a quarterly basis, Capital Leases fell 2.53% year-over-year to $54.6 million in Q2 2026; TTM through Jun 2026 was $54.6 million, a 2.53% decrease from a year earlier, with the FY2025 full-year figure at $54.9 million, down 3.45% from the prior year.
• Capital Leases was $54.6 million for Q2 2026 at Amneal Pharmaceuticals, roughly flat from $54.9 million in the prior quarter.
• The five-year high for Capital Leases was $61.3 million in Q3 2022, with the low at $54.6 million in Q2 2026.
• Average Capital Leases over 5 years is $58.0 million, with a median of $58.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Capital Leases gained 0.86% in 2022, then decreased 3.75% in 2025.
• Over 5 years, Capital Leases stood at $60.8 million in 2022, then dropped by 3.63% to $58.6 million in 2023, then slipped by 2.86% to $56.9 million in 2024, then slipped by 3.45% to $54.9 million in 2025, then dropped by 0.59% to $54.6 million in 2026.
• The last three Capital Leases figures came in at $54.6 million (Q2 2026), $54.9 million (Q1 2026), and $54.9 million (Q4 2025), per Business Quant data.